History & Overview Annual Report President's Pages Center News Community Affairs Code of Conduct
Make a Gift Cycle for Survival Fred's Team Yankees Universe Fund Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck CELEBRATIONS
Press Releases In the News Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days IS Careers Job Search & Apply Online
  1. German PS, Hoey JR, Horky R, Levine DM, Skinner EA, West SK, Zauber AG. Symposium: Health care of the aged in four ambulatory settings with a focus on the hypertensive patient. Gerontologist 1975; 15:311.

  2. West SK, Brandon BM, Stevens AM, Zauber AG, Chase GA, Stolley PD, Rumrill RE. Drug utilization in an HMO: 1. Introduction and examples of methodology. Med Care 1977; 15:505-514.

  3. Skinner EA, German PS, Shapiro S, Chase GA, Zauber AG. Use of ambulatory health service by the near poor. Am J Pub Health 1978; 68:1195-1201.

  4. Schottenfeld D, Morgan RW, Zauber AG. Questions raised by study on cancer mortality in oil refinery workers. Journal of Occupational Medicine 1980; 2 :69-70.

  5. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980; 112:232-246.

  6. Fisher B, Montague E, Redmond C, Deutsch M, Brown GR, Zauber AG, Hanson WF, Wong A. Findings from NSABP protocol no. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcomes. Cancer 1980; 46:1-13.

  7. Miransky J, Kerner JF, Sturgeon SR, Zauber A, Strickman NA, senie RT, Anderson r. A comparison of primary breast cancer management in small, intermediate and large community hospitals and a comprehensive cancer center. Prog Clin Biol Res 1984;156:87-96.

  8. Kerner JF, Winn R, Robertson P, Zauber A, Bleadingheiser LJ. An MSKCC-Community hospital colorectal carcinoma audit: a cancer control project. Prog Clin Biol Res 1983;120:79-84.

  9. Schottenfeld D, Zauber AG, Kerner JF, Warshauer ME. Recent trends in cancer survival. Trans Assoc Life Insur Med Dir Am 1986; 69:66-86.

  10. Zauber NP, Zauber AG. Hematologic data of healthy very old people. JAMA 1987; 257:2181-2184.

  11. Kerner JF, Andrews H, Zauber AG, Struening E. Geographically-Based Cancer Control: Methods for targeting and evaluating the impact of screening interventions on defined populations. J Clin Epidemiol 1988, 41:543-553.

  12. Kushner BH, Zauber AG, Tan CT. Second malignancies after childhood Hodgkin's disease. Cancer 1988; 62:1364-1370.

  13. Winawer SJ, Zauber A, Diaz B, O'Brien M, Gottlieb LS, Sternberg SS, Waye JD, Shike M. The National Polyp Study: overview of program and preliminary report of patient and polyp characteristics. Prog Clin Biol Res 1988; 279:35-49.

  14. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, Dickersin R, Ewing S, Geller S, Dasimian D, Komorowski R, Szporn A, National Polyp Study Workgroup. The National Polyp Study: Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98:371-379.

  15. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. Vasectomy and the risk of prostate cancer. Am J Epidemiol 1990; 132:1051-5.

  16. Winawer SJ, O'Brien MJ, Waye JD, Kronborg O, Bond J, Fruhmorgen P, Sobin LH, Burt R, Zauber A, Morson B, WHO Collaborating Center for the Prevention of Colorectal Cancer. Risk and surveillance of individuals with colorectal polyps. WHO Bulletin 1990; 68(6):789-795. Reprint No. 5136.

  17. Winawer SJ, Zauber AG, Stewart E, O'Brien MJ. The natural history of colorectal cancer: Opportunities for intervention. Cancer 1991; 67:1143-1149.

  18. Fleisher M, Winawer SJ, Zauber AG, Smith C, Schwartz MK, National ­Polyp Study Workgroup. Accuracy of fecal occult blood test inter­preta­tion. Ann Int Med, 1991; 114:875-6.

  19. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A Hypothesis: NSAIDs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83:355-58.

  20. Palmer JR, Rosenberg L, Clarke EA, Stolley PD, Warshauer ME, Zauber AG, Shapiro S. Breast Cancer and Cigarette Smoking: A Hypothesis. Am J Epidemiol 1991; 134:1-13.

  21. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Urmacher C, Brennan M. Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT. Radiol 1991; 181:419-425.

  22. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Winawer SJ, Urmacher C, Brennan M. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiol 1991; 181:426-432.

  23. Mandelblatt J, Andrews H, Kerner J, Zauber A, Burnett W. Determinants of late stage diagnosis of breast and cervical cancer: the impact of age, race, social class and hospital type. Am J Pub Health 1991; 81:646-649.

  24. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer E, Zauber AG, Shapiro S. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991; 134:1375-85.

  25. Johannes CB, Kaufman DW, Rosenberg L, Palmer JR, Stolley PD, Lewis Jr. JL, Zauber AG, Warshauer ME, Shapiro S. Side of origin of epithelial ovarian cancer. Br Med J 1992; 304:27-28.

  26. Zauber NP, Zauber AG, Gordon FJ, Tillis AC, Leeds HC, Berman E, Kudryk AB. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992; 267:525-527.

  27. Dusenbury L, Kerner J, Baker E, Botvin G, James-Ortoz S, Zauber A. Predictors of smoking prevalence among New York latino youth. Am J Pub Health 1992; 82:55-58.

  28. Robinson E, Zauber A, Fuks Z, Strong E. Clinical characteristics of patient swith epidermoid carcinoma of the upper aerodigestive tract who develop second malignant tumors. Cancer Detect Pre 1992;16(5-6):297-303.

  29. Winawer SJ, Zauber AG, O'Brien MJ, Gottlieb LS, Sternberg SS, Stewart ET, Bond JH, Schapiro M, Panish JF, Waye JD, Kurtz RC, Shike M, Ho MN, The National Polyp Study Workgroup. Design, methods and characteristics of patients with newly diagnosed polyps. Cancer 1992; 70:1236-1245.

  30. O'Brien MJ, O'Keane JC, Zauber AG, Gottlieb LS, Winawer SJ. Precursors of colorectal carcinoma: biopsy and biological markers. Cancer 1992; 70:1317-27.

  31. Palmer JR, Rosenberg L, Strom BL, Harlap S, Zauber AG, Warshauer ME, Shapiro S. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992; 3:547-54.

  32. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, Waye JD, Bond J, Schapiro M, Stewart ET, Panish J, Ackroyd F, Kurtz RC, Shike M, National Polyp Study Workgroup. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993; 328:901-6..

  33. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shike M, Kurtz RC, Hornsby-Lewis L, Gerdes H, Stewart ET, National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329:1977-81.

  34. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Stewart ET, Bond JH, Schapiro M, Panish JF, Waye JD, Kurtz RC, Shike M, National Polyp Study Workgroup. The National Polyp Study. Eur J Cancer Prev 1993; 2Suppl:83-87.

  35. Andrews H, Kerner JF, Zauber AG, Mandelblatt J, Pittman J, Struening E. Using census and mortality data to target small areas for breast, colorectal, and cervical cancer screening. Am J Publ Hlth 1994; 84:56-61.

  36. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shapiro S. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994; 139:654-61.

  37. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Strom BL, Harlap S, Shapiro S. The relation of vasectomy to the risk of cancer. Am J Epidemiol 1994; 140:1-8.

  38. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Strom BL, Harlap S, Shapiro S. The relation of benzodiazepine use to the risk of selected cancers: Breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid and liver. Am J Epidemiol 1995;141:1153-1160.

  39. Boivin J-F, Hutchinson CB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B , Tan CTC, Mauch P, Ultmann JE. The incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995;87:732-741.

  40. Palmer JR, Rosenberg L, Harlap S, Strom BL, Warshauer ME, Zauber AG, Shapiro S. Adult height and risk of breast cancer among US black women. Am J Epidemiol 1995;141(9):845-849.

  41. Zauber AG, Winawer SJ. Colonoscopic polypectomy reduces the incidence of colorectal cancer: Results of the National Polyp Study. Proceedings of the Association of American Physicians. 1995;107:205-210.

  42. Palmer JR, Rosenberg L, Rao RS, Strom BL, Warshauer ME, Harlap S, Zauber A, Shapiro S. Oral contraceptive use and breast cancer risk among African-American Women. Cancer Causes Control 1995;6:321-331.

  43. Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ, Gottlieb LS, Sternberg SS, Bond JH, Waye JD, Schapiro M, Panish JF, Kurtz RC, Shike M, Ackroyd FW, Stewart ET, Bishop DT, National Polyp Study Workgroup. Risk of colorectal cancer in families of people with adenomatous polyps. N Engl J Med 1996;334:82-87.

  44. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Strom BL, Harlap S, Shapiro S. A case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996;143:25-37.

  45. Zhang Y, Rosenberg L, Colton T, Cupples LA, Palmer JR, Strom BL, Zauber AG, Warshauer ME, Harlap S, Shapiro S. Adult height and risk of breast cancer among white women in a case-control study. Am J Epidemiology 1996;143:1123-1128.

  46. Koblin BA, Hessol NA, Zauber AG, Taylor PE, Buchbinder SP, Katz MH, Stevens CE. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990. Am J Epidemiol 1996;144:916-23.

  47. Palmer JR, Rosenberg L, Rao RS, Zauber AG, Strom BL, Warshauer ME, Stolley, PD, Shapiro S. Induced and spontaneous abortion in relation to risk of breast cancer (United States). Cancer Causes and Control 1997:8:841-849.

  48. Rosenberg L, Rao RS, Palmer JR, Strom Bl, Zauber A, Warshauer ME, Shapiro S. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 1998;9:83-88.

  49. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shaprio S. Calcium channel blockers and the risk of cancer. JAMA 1998; 279:1000-1004.

  50. Harlap S, Zauber AG, Pollack DM, Tang J, Arena AE, Sternfels P, Borgen P, Norton L. Survival of premenopausal women with breast carcinoma: effects of menstrual timing of surgery. Cancer 1998;83:76-88.

  51. Olson SH, Zauber AG, Tang J, Harlap S. Relation of time since last birth and parity to survival of young women with breast cancer. Epidemiology 1998; 9:669-671.

  52. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Stolley PD, Zauber AG, Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999;2:72-76.

  53. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. American Journal of Epidemiology 1999; 150:861-868.

  54. Ostroff J, Garland J, Moadel A, Fleshner N, Hay J, Cramer L, Zauber A, Trambert R, O'Sullivan ME, Russo P. Cigarette smoking patterns in patients after treatment of bladder cancer. J Cancer Educ 2000;15:86-90.

  55. Coogan PF, Rosenberg L, Palmer JR, Strom, BL, Zauber AG, Stolley PD, Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiology, Biomarkers and Prevention 2000;9:119-123.

  56. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines. Cancer Causes Control 2000; 11:839-845.

  57. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes and Control 2000; 11:249-255.

  58. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, Hall D, Hamlin JA, Schapiro M, O'Brien MJ, Sternberg SS, Gottlieb LS, Hogan WJ, Khilani M, Ackroyd FW, Panish JF, Kussin L, Edelman M. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. N Engl J Med 2000; 342:1766-72.

  59. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiology Biomarkers & Prevention 2000; 9:933-937.

  60. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. Phenolphthalein laxatives and risk of cancer. J Natl Cancer Inst 2000;92:1943-1944.

  61. Zauber NP, Sabbath-Solitare M, Marotta SP, Zauber AG, Bishop DT. Molecular changes in the Ki-ras and APC genes in colorectal adenomas and carcinomas arising in the same patient. J of Pathology 2001;193:303-309.

  62. Coogan PF, Rosenberg L, Palmer J, Strom BL, Zauber AG, Shapiro S. The relationship of statin use to the risk of breast and prostate cancer. Epidemiology 2002; 13:262-267.

  63. Blackman JA, Coogan PF, Rosenberg L, Strom BL, Zauber AG, Palmer JR, Langenberg P, Shapiro S. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf. 2002; 11:61-7.

  64. van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. August, 2003 http://www.cms.hhs.gov/coverage/download/id87.zip

  65. Loeve F, Boer R, Zauber AG, van Ballegooijen M, van Oortmarssen GJ, Winawer SJ, Habbema JD. National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004;111:633-9.

  66. O'Brien MJ, Winawer SJ, Zauber AG, Bushey MT, Sternberg SS, Gottlieb LS, Bond JH, Waye JD, Schapiro M. Flat Adenomas in the National Polyp Study: Is There Increased Risk for High-grade Dysplasia Initially or During Surveillance? Clinical Gastroenterology and Hepatology 2004; 2:905-911.

  67. Zauber P, Sabbath-Solitare M, Marotta S, Zauber A, Bishop T. Comparative molecular pathology of sporadic hyperplastic polyps and neoplastic lesions from the same individual. J Clin Pathol 2004: 57:1084-1088.

  68. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-80.

  69. Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes W, Chan M, Turner F, Bishop DT. Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer 2005;104:719-29.

  70. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer: and the American Cancer Society. Joint publication in Gastroenterology 2006:130:1872-85 and CA Cancer J Clin 2006;56:143-59.

  71. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim KM, Tang J, Rosenstein RB., Janet Wittes, Ph.D., Donald Corle, M.S., Timothy M. Hess, M.S., G. Mabel Woloj, Ph.D., William F. Anderson, M.D., M.P.H., Jaye L. Viner, M.D., M.P.H., Donya Bagheri, M.S., D.A.B.T., Gary B. Gordon, M.D., Ph.D., Frederic Boisserie, John Burn, M.D., Daniel C. Chung, M.D., Thomas Dewar, M.D., T. Raymond Foley, M.D., Neville Hoffman, M.D., Finlay Macrae, M.D., Ronald E. Pruitt, M.D., John R. Saltzman, M.D., Bruce Salzberg, M.D., Thomas Sylwestrowicz, M.D., Ernest T. Hawk, M.D., M.P.H. for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Prevention of Sporadic Colorectal Adenomas with Celecoxib: Results of a Randomized Trial .N Engl J Med 2006;355:873-84.

  72. Arber N, Eagle C, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.

  73. Solomon SD, Pfeffer MA, McMurray JJV, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli M, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for prevention of colorectal adenoma. Circulation 2006,114:1028-1035.

  74. Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JDF, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the US? Mortality projections for scenarios of risk factor modification, screening and treatment. Cancer 2006;107:1624-33.

  75. Olson SH, Orlow I, Simon J, Tommasi D, Roy P, Bayuga S, Ludwig E, Zauber AG, Kurtz RC. Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev. 2007;31(5):345-51. Epub 2007 Nov 26.

  76. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. Available from: https://www.cms.hhs.gov/mcd/viewtechassess.asp?from2=viewtechassess.asp&id=212& 2007.

  77. Brooks DD, Winawer SJ, Rex DK, Zauber AG, Kahi CJ, Smith RA, Levin B, Wender R; U.S. Multi-Society Task Force on Colorectal Cancer; American Cancer Society. Colonoscopy surveillance after polypectomy and colorectal cancer resection. Am Fam Physician. 2008 Apr 1;77(7):995-1002.

  78. Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila Pa). 2008 Jun;1(1):21-31. Epub 2008 Apr 14.

  79. Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care. 2008 Sep;46(9 Suppl 1):S91-6.

  80. Zauber AG, Levin TR, Jaffe CC, Galen BA, Ransohoff DF, Brown ML. Implications of new colorectal cancer screening technologies for primary care practice. Med Care. 2008 Sep;46 (9 Suppl 1):S138-46.

  81. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer. 2009 Mar 1;124(5):1161-8.

  82. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Nov 4;149(9):659-69. Epub 2008 Oct 6. Summary for patients in: Ann Intern Med. 2008 Nov 4;149(9):I-44.

  83. Olson SH, Orlow I, Bayuga S, Sima C, Bandera EV, Pulick K, Faulkner S, Tommasi D, Egan D, Roy P, Wilcox H, Asya A, Modica I, Asad H, Soslow R, Zauber AG. Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control. 2008 Nov;19(9):955-63. Epub 2008 Apr 25.

  84. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DF, Rosenstein RB, Eagle CJ, Hawk EJ, Bertagnolli MM. Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology 2009 Feb 19. [Epub ahead of print].

  85. Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM. Cost-effectiveness of CT colonography to screen for colorectal cancer. Technology Assessment Report. Project ID CTCC0608 for Agency for Health Care Quality from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN, SimCRC, and CRC-SPIN models. January 22, 2009 http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=58

  86. Martinez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, Zauber AG, Jian R, Ahnen DN, Bond JH, Church TR, Robertson DF, Smith-Warner, SA, Jacobs ET, Alberts DS. Greenberg ER. A pooled analysis of advanced colorectal neoplasia diagnosis after colonoscopic polypectomy. Gastroenterology 2009 Mar;136(3):832-41. Epub 2008 Dec 9.

  87. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.Cancer Prev Res (Phila Pa). 2009 Apr;2(4):310-21.

  88. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Nov 4;149(9):659-69.

  89. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer. 2009 Mar 1;124(5):1161-8.

  90. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer. 2009 Jun 1;115(11):2410-9.

  91. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ, Habbema JD. Individualizing colonoscopy screening by sex and race. Gastrointest Endosc. 2009 Jul;70(1):96-108, 108.e1-24.

  92. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009 Oct 21;101(20):1412-22.

  93. Rutter CM, Kuntz KM, Zauber AG; Colorectal Cancer Modeling Group in the Cancer Intervention and Surveillance Modeling Network. Extracolonic findings from CTC: balancing risks and benefits. AJR Am J Roentgenol. 2009 Nov;193(5):W470

  94. Lambert R, Kudo SE, Vieth M, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O'Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Jass JR, Triadafilopoulos G. Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointest Endosc. 2009 Dec;70(6):1182-99.

  95. Ma J, Liu W, Zhang L, Pan K, Zhao H, Zhou T, Winawer S, Zauber A, Classen M, You W. A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial. Eur J Gastroenterol Hepatol. 2009 Dec 5.

  96. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. Epub 2009 Dec 7. 2010; 116;544-73.

Return to Ann Zauber Main Page
Bookmark and SharePrintEmail This Page